Cell and Gene Outsourcing

  1. Custom Media Development Services 11/14/2025

    Leverage custom media development services to optimize formulations for increased titers, quality, and manufacturability. Choose between traditional or multi-omics workflows to meet your cell line's specific needs.

  2. Biologically Expressed vs. Synthetic GLP-1 Peptides 11/14/2025

    Selecting the right GLP-1 peptide manufacturing route determines the specific impurity profile and regulatory strategy. Robust analytical methods are essential for ensuring efficacy and patient safety.

  3. Annex 1: Ensuring Sterile Pharmaceutical Manufacturing Standards 11/13/2025

    Adhering to the rigorous standards set by the EMA's Annex 1 requires strategic, risk-based compliance for facility design and processes, all of which is key to patient safety and future innovation.

  4. The Shift Toward Flexible FSP Models 11/13/2025

    Flexible FSP models are reshaping clinical outsourcing by offering sponsors scalable, cost-predictable partnerships that preserve control, enhance quality, and support long-term strategic goals.

  5. Delivering Therapies Without Delay Using An Integrated Platform 11/13/2025

    Eliminating discontinuity between R&D and cGMP manufacturing, through mirrored environments, accelerates the journey to IND and patient access and bypasses delays in clinical transfer.

  6. Viral Vector Technology Transfers: A Guide To Success 11/13/2025

    Strategic, well-aligned partnerships between sponsors and CDMOs are key to efficient, scalable viral vector technology transfer.

  7. A Review Of The Twelve Principles Of Green Chemistry 11/11/2025

    Prevention and design are foundational to green chemistry, requiring foresight to minimize hazards from the start. Reducing reliance on solvents is a critical step toward sustainability.

  8. Manufacturing Of CAR-T Cells: Automation And Defined Culture Conditions 11/11/2025

    The process associated with the manufacture of CAR-T cell therapies presents challenges that immensely impact patient accessibility to these treatments. Reducing manufacturing complexity is key.

  9. High Potency Active Pharmaceutical Ingredients 11/10/2025

    Safely manufacturing HPAPIs and cytotoxic compounds requires specialized expertise and purpose-built facilities. Discover solutions from process development to commercial scale, including for ADC payloads.

  10. What Researchers Should Look For When Choosing A CLD Partner 11/7/2025

    A strong track record in compliant saline production and scalable quality is key when selecting a biomanufacturing partner. See how these factors help ensure regulatory alignment and long-term success.